Summary
Introduction
The demonstration that bradykinin releases prosta-glandin Ea (McGiff, Terragno, Malik & Lonigro, 1972 ) from the kidney led to the hypothesis that some of the actions of the renal kallikrein-kinin system are related to this effect (McGB & Itskovitz, 1973) . We have studied the effects of bradykinin on renal function before and after inhibition of prostaglandin synthesis by indomethacin (Vane, 1971) and have compared these changes with those produced by another vasodilator polypeptide, eledoisin, which does not release prostaglandins from the kidney. Both polypeptides were infused at rates which produced a similar degree of renal vasodilatation. Comparison of the renal response to bradykinin, before and after administration of indomethacin, should relate to the inability of the kinin to release prostaglandins after inhibition of prostaglandin synthesis. In contrast, the action of eledoisin should be unaffected by indomethacin.
Canine blood-perfused isolated kidneys were used in order to restrict the study to those factors of renal origin which affect the interactions of kinins and prostaglandins. Circulating vasoactive substances of extrarenal origin were thus excluded and variations in perfusion pressure and cardiopulmonary performance which might obscure definition of these hormonal relationships were prevented. In the isolated kidney, pulse rate, perfusion pressure, blood gases and chemical composition of the blood can be regulated to simulate physiological conditions and blood flow made similar to that occurring in uivo. Further, the function of the isolated canine kidney is stable for more than 5 h.
Methods
Mongrel dogs weighing 15-20 kg were killed with pentobarbitone, 261 pmol (65 mg)/kg body weight, intravenously. Their kidneys were removed and transferred to a lucite perfusion chamber within 2 rnin (Berkowitz, Miller & Itskovitz, 1967) . The isolated kidney was perfused with 70C800 ml of autologous heparin-treated blood, which was recirculated by a Waters pump oxygenator system delivering a pulsatile blood flow at 70 strokeslmin. The perfusion pressure was monitored continuously by a Tycos manometer and kept constant by changing renal blood flow to maintain a systolic pressure of 140 mmHg. Mean renal perfusion pressure was maintained between 115 and 120 mmHg. Blood pH, Poz and Pco, were measured at 30 rnin intervals and maintained within physiological ranges by delivering various mixtures of air, oxygen and carbon dioxide into the oxygenator. Blood was kept at 37°C by passage through a coil immersed in a constant-temperature water bath. Replacement fluids, electrolytes and other chemicals (including sodium, calcium, magnesium, chloride, phosphate, bicarbonate, creatinine and urea) were added to the perfusate through venous ports to maintain physiological concentrations, which were verified by blood analyses. Glucose (5.6 pmol/min), lactate (50 pmol/min) and pyruvate (5.1 pmol/min) were added also as metabolic substrates for the kidney. Insulin and antidiuretic hormone were infused at rates of 0.01 unitlmin and 0.001 unitlmin respectively. Glomerular filtration rate was measured as the clearance of creatinine. Total renal blood flow was measured directly by timed collections of the renal venous effluent. The intrarenal distribution of blood flow was assessed by using microspheres of 15-20 pm diameter labelled with 169Yb, 85Sr, 141Ce, "Cr or 46Sc (Minnesota, Mining and Manufacturing Co.) . For this purpose we adapted the technique of McNay & Abe (1970) to the isolated kidney as described by Itskovitz, Hebert & McGiff (1973) . A portion (1-4 pCi) of microspheres was injected into the perfusion circuit just proximal to the perfusion pump, 8.4 m from the kidney. This distance between injection site and the kidney is greater than can be achieved in vivo and favours adequate mixing of the microspheres in the perfusate. To ensure representative sampling, at least twelve tissue specimens were obtained from four equal cortical zones of each kidney to count the radioactivity of their isotope contents and to calculate mean distribution ratios and blood flows to the outer and inner cortex (zones C1, Cz and CJ, C4 respectively of McNay & Abe, 1970) . These represent approximate outer and inner halves of the renal cortex.
A rapid increase in renal blood flow of 4C60% above the initial value occurs within the first 1-2 h after removal of the kidney (Itskovitz & McGiff, 1974) and this would have obscured the effects of vasodilator agents. Between the second and fifth hours of perfusion of the isolated kidney, blood flow usually increases by another 15-30% (Itskovitz & McGiff, 1974) . Accordingly, the first control periods (Tables 1 and 2) were begun on an average of 90 rnin after isolating the kidney and subsequent periods were separated by intervals of 10-20 min. In order to minimize the time-related changes in blood flow, the effects of infusing bradykinin and eledoisin on renal blood flow and its fractional distribution to the inner cortex were measured within 5 min of starting the infusion, when the vasodilator response was sustained. All the other values shown in the Tables were obtained from urine collected over periods of 30 min. For those values which required blood samples in addition to urine samples for the calculation, namely, creatinine for GFR'') and plasma osmolality for free water clearance, blood was collected midway through the period.
During periods 2 and 5 of the Tables either bradykinin or eledoisin was infused. Indomethacin was given between periods 3 and 4. Bradykinin, 18.8-84.9 pmol (20-90 ng) min-kg-l, and eledoisin, 83.8-335.2 pmol (100-400 ng) min-' kg-l, were administered into the arterial side of the circuit at rates which increased renal blood flow by approximately 30% of control flow. After 20 min, another 30 min clearance period was obtained to provide preindomethacin values. Indomethacin, 2.8-8.4 pmol (1-3 mg), was then injected slowly into the perfusion circuit to inhibit prostaglandin synthesis. The immediate effect of this was to cause a decrease in renal blood flow of about 30%. At 20 rnin after administration of indomethacin, control observations were taken for an additional 30 min, after which either bradykinin or eledoisin was infused, at the same rate as before administration of indomethacin, for another period of 30 min.
Creatinine was determined by autoanalyser, sodium by flame photometry and osmolality by a 
CHZO time (min)
(ml/min) (%) (ml/min) (ml/min) Umol/min) (mosmol/l) ( EN. =(UN..V/FN.) x 100 where UN..V=urinary sodium excretion (,umol/min), F N n =filtered sodium = PNa.GFR, where PN. =plasma sodium concentration (nmol) and GFR =glomerular filtration rate (ml/min as estimated by creatinine clearance). Indomethacin was dissolved in 10 ml of ethanol and diluted with Krebs solution to give a final concentration of 2.8 pmol (1 mg)/ml. This in turn was diluted in 700 ml of blood, the volume of this perfusion circuit. Synthetic bradykinin (Schwarzl Mann) and synthetic eledoisin (Sandoz Pharmaceuticals) were diluted in 150 mmol/l sodium chloride on the day of the experiment.
Differences between values for the successive perfusion periods and differences between periods before and after indomethacin were determined by Student's t-test. A P value of 0.05 or less was considered statistically significant. Statistical analyses were performed according to methods described by Steel & Torrie (1960) .
Results

Control studies
The two Tables show changes in renal haemodynamics and function during five successive 30 min periods for two groups, consisting of five experiments in each. In .one group bradykinin (Table l) , and in the second eledoisin (Table 2) , was administered before and after administration of indomethacin. The values during period 1, the control period, were similar for each group. Bradykinin and eledoisin differed primarily in their effects on the excretion of solute-free water. A timedependent decrease in urinary osmolality and increase in free water clearance ( ( 2~~~) occur in the isolated kidney (Berkowitz et al., 1967) . These changes were enhanced by infusion of bradykinin, which decreased U , , , . by 116 mosmol/l (P<0-025) and increased CHzO by 0.30 ml/min (P<0.025). Increased Uosm. and CHzO produced by bradykinin were reflected in the undiminished urinary volume despite a large reduction in GFR. In contrast, infusion of eledoisin was associated with an increase in CHzO of 0-13 ml/min and decrease in U. . , .
of 53 mosmol/l, neither of which was significant, but a significant (P<0.05) decrease in urinary volume of 0.37 ml/min. Increased solute-free water excretion, in response to bradykinin, was observed even in those instances when Uo,,,,. was low. In those two of the five experiments which had the lowest U,,,., 292 and 350 mosmol/l, decreases of 65 and 98 mosmol/l respectively occurred during infusion of bradykinin. When changes in CHZo were expressed per 100 ml of GFR, differences between the effects of bradykinin and eledoisin on excretion of solute-free water became even more pronounced, namely, CHzo/lOO ml GFR increased by a mean of 1.31 ml/min (P<O.OI) during infusion of bradykinin, whereas an increase of 0.45 ml/min (P > 0.05) occurred during infusion of eledoisin. Mean plasma osmolality, 3 11 k 2 mosmol/l, was unaffected by either agent. Bradykinin and eledoisin increased mean renal blood flow and its fractional distribution to the inner cortex significantly. From mean control flows of 169 and 165 ml/min, infusions of bradykinin and eledoisin increased renal blood flow to 234 and 233 ml/min respectively, and the percentage of renal blood flow perfusing the inner cortex increased by mean values of 13% (bradykinin) and 12% (eledoisin). Each polypeptide decreased GFR by approximately 7 ml/min (P <0.05). GFR remained depressed after the infusion of bradykinin was discontinued, whereas G F R recovered on stopping eledoisin. Eledoisin and bradykinin decreased sodium excretion by mean values of 68 and 39 wnol/min, significant (P<0.05) only in the former case. This was primarily due to reduced GFR, since fractional excretion of sodium was unaffected and plasma sodium remained unchanged (range 148-1 55 mmOl/l).
Efects of indomethacin
Indomethacin administration resulted in a significant (Pt0.025) reduction of renal blood flow in each group. From similar mean values of 226 and 220 ml/min, renal blood flow decreased to 147 and 158 ml/min in the bradykinin and eledoisin groups respectively. The GFR of the eledoisin group fell from 19.2 ml/min to 13.3 mllmin (P<0*025), a value similar to the GFR of the bradykinin group. The latter was not affected by indomethacin, since it was already depressed, having failed to recover from the initial infusion of bradykinin. Urinary volume, sodium excretion and excretion of solutefree water were not modified by indomethacin in either group. Uos,,,, was significantly reduced only in the eledoisin group.
After indomethacin administration
The renal vasodilator response to eledoisin was unaffected, i.e. significant increases of 68 and 63 ml/min occurred before and after administration of indomethacin respectively. In contrast, the increase in renal blood flow evoked by bradykinin was reduced from 65 to 44 ml/min after administration of indomethacin. This latter change was not significant. However, changes in the distribution of cortical blood flow in response to bradykinin were not modified by indomethacin since fractional blood flow to the inner cortex was increased to a similar degree before and after its administration. GFR was decreased further by eledoisin, which was associated with reduction in mean urinary volume from 1-29 to 0.79 ml/min (Pc 0-05). Although bradykinin did not affect GFR, sodium excretion increased from 61 to 112 pmol/min, which also represented a significant increase in the excretion of the filtered load of sodium. Before administration of indomethacin, excretion of sodium was 3.8% and 3.1 % of the filtered load for control and bradykinin infusion periods respectively (P z 0.05), whereas after indomethacin bradykinin increased fractional sodium excretion from 3.3 to 4.7% (P< 0.05). After indomethacin, neither polypeptide affected CHIO or Uosm. significantly. Although the low Uos,. at this time contributed to the failure of bradykinin to affect excretion of solute-free water, it cannot account entirely for this failure. Thus in the one experiment post-indomethacin in which Uos,. (356 mosmolll) was comparable with those values found before indomethacin, bradykinin was still without effect on U,,,.
Discussion
The effect of bradykinin on renal blood flow and on the urinary concentrating mechanism may be partly related to its ability to release prostaglandin Ez from the kidney. This interpretation is supported by the following observations from the current studies. First, the renal vasodilator action of bradykinin was attenuated after inhibition of prostaglandin synthesis by indomethacin; the effects of bradykinin on urinary osmolality and free water clearance differed from those of eledoisin before, but not after, administration of indomethacin. Secondly, bradykinin affects renal function similarly to prostaglandin E2 (Martinez-Maldonado, Tsaparas, Eknoyan & Suki, 1972) when given before, but not after, inhibition of prostaglandin synthetase. Thirdly, the effects of eledoisin, also a vasodilator polypeptide, on renal blood flow were not modified by indomethacin. It is known that eledoisin, in contrast to bradykinin, does not release renal prostaglandins (McGiff et al., 1972) . Indomethacin, however, possesses other actions as well as inhibition of prostaglandin synthesis (Flores & Sharp, 1972) . The experimental design permitted detection of those effects unrelated to inhibition of prostaglandin synthetase. Thus non-speci€ic effects of indomethacin should have been detected by alteration of the action of both bradykinin and eledoisin. Since the renal actions of eledoisin were unaffected by indomethacin, we assumed that modification of the actions of bradykinin on renal blood vessels and the urinary concentrating mechanism by indomethacin was consequent to inhibition of prostaglandin synthetase. Although we did not measure changes in the concentration of prostaglandin E2 produced by indomethacin, we have previously observed that indomethacin administered in similar doses decreased the blood prostaglandin E2 by more than 70% in the dog (Itskovitz & McGiff, 1974) and resulted in the inability of the kidney to convert arachidonic acid into prostaglandins, indicating inhibition of prostaglandin synthesis (Lonigro, Itskovitz, Crowshaw & McGiff, 1973) . Thus, within 30 min of administration of indomethacin into the blood perfusing the isolated canine kidney, the concentration of prostaglandin Ez decreased from mean blood concentrations of 1 a12 ng/ml to 0.28 ng/ml (Itskovitz & McGiff, 1974) . Moreover, effective inhibition of prostaglandin synthesis persists for at least 3 h in the isolated kidney. This far exceeds the time required to complete the present experiments. In those previous studies, we have also found that another anti-inflammatory acid, meclofenamate, did not differ from indomethacin in its effects on either prostaglandin synthesis or function in the isolated kidney.
Changes in the excretion of water produced by bradykinin before indomethacin were indicated by the consistent reduction in urinary osmolality and increased excretion of water free of solute. The effect of bradykinin on excretion of water was &st described by Barraclough & Mills (1964) .
If these changes are related to the release of a prostaglandin E-like substance within the kidney by the kinin, then inhibition of antidiuretic hormone by prostaglandin El may contribute to the effects of bradykinin on water excretion. The ability of prostaglandins of the E series to antagonize the effects of antidiuretic hormone was among the first demonstrations of modulation by a prostaglandin of the biological activity of a polypeptide (Grantham & Orloff, 1968) . In the present experiments, vasopressin was added continuously in excess to the perfusate. These results also support the proposal of Adetuyibi & Mills (1972) that there are two renal mechanisms affecting kallikrein release and hence kinin generation within the kidney. The first is related to excretion of water and is independent of changes in sodium excretion; the second mechanism is related to sodium excretion. Thus, before administration of indomethacin, bradykinin affected water excretion independently of sodium excretion.
A clear relationship between renal prostaglandin synthesis and sodium excretion did not emerge from the present study. Bradykinin increased sodium excretion after, but not before, administration of indomethacin. However, the large reduction in GFR produced by bradykinin infusion, before administration of indomethacin, would have prevented the demonstration of a natriuresis. Further, release of endogenous prostaglandin Ez by bradykinin will affect sodium reabsorption differently from exogenous prostaglandin Ez ; the latter usually increases sodium excretion. Thus the primary site of action of exogenous prostaglandin Ez may be the renal cortex whereas that of the endogenous prostaglandin El may be the renal medulla. Further, their activities may be mainly conlined to these sites, cortex or medulla, because of the high activity of metabolizing enzymes in the renal cortex, which should contribute to the segregation of the effects of endogenous and exogenous prostaglandins (Larsson & k g g i r d , 1973) . In addition, other factors such as the type of prostaglandin released may determine the effect of endogenous prostaglandins on sodium excretion. Finally, it is by no means certain that prostaglandin E2 inhibits sodium transport directly, since stimulation of sodium transport has been shown in the isolated toad bladder (Lipson & Sharp, 1971) .
This study also showed a dissociation between sodium excretion and fractional distribution of renal blood flow. Thus bradykinin increased fractional blood flow to the inner (juxtamedullary) cortex similarly before and after indomethacin, although in the first instance sodium excretion usually declined. After indomethacin, however, sodium excretion doubled. Redistribution of blood flow in the isolated kidney, therefore, does not seem to be a major determinant of sodium excretion.
The present study indicates that one or more renal prostaglandins amplify the renal vasodilator action of bradykinin and mediate the effect of bradykinin on urinary osmolality and excretion of water. Three kinds of activity, each effected by the principal renal prostaglandin, prostaglandin Ez, may now be identified.
(1) Modulation: prostaglandin Ez not only attenuates the renal vascular action of the vasoconstrictor-antidiuretic hormones, angiotensin I1 and noradrenaline (McGiff, Crowshaw, Terragno & Lonigro, 1970; Aiken & Vane, 1973) , but also amplifies the renal vasodilator actions of kinins.
(2) Maintenance: continuous synthesis of prostaglandin EZ by the kidney probably contributes to maintaining total renal blood flow (Lonigro et al., 1973) , particularly its medullary and inner cortical components (Itskovitz & McGiff, 1974 and may determine the action of bradykinin on the urinary concentrating mechanism.
